产品管线 - CRISPR Therapeutics拥有广泛的产品管线,包括用于治疗血红蛋白病、肿瘤、再生医学、心血管疾病、自身免疫疾病和罕见疾病的产品[28] - 正在进行下一代CAR-T产品CTX112和CTX131的临床试验,分别针对CD19和CD70[3,12,15] - 正在进行体内基因编辑产品CTX310和CTX320的临床试验,分别针对ANGPTL3和LPA[16] - 正在进行CTX211治疗1型糖尿病的临床试验[18] 获批情况 - CASGEVY已在美国、英国、欧盟、沙特阿拉伯和巴林获批上市,用于治疗镰状细胞病和输血依赖性β地中海贫血[10] - CRISPR Therapeutics在2023年底获批CASGEVY™(exagamglogene autotemcel [exa-cel])用于治疗适合患者的镰状细胞病或输血依赖性β地中海贫血[28] 临床进展 - 截至7月中旬,全球已有超过35家授权治疗中心启用,约20名患者已完成细胞采集[2] - 已开启CTX112治疗系统性红斑狼疮和CTX131治疗血液恶性肿瘤的临床试验[14,15] 财务情况 - 截至2024年6月30日,公司现金及等价物约为20.13亿美元[20] - 2024年第二季度CRISPR Therapeutics的总收入为517,000美元,主要来自于授权收入[34] - 2024年第二季度CRISPR Therapeutics的研发费用为80,165,000美元,管理费用为19,481,000美元[34] - 2024年第二季度CRISPR Therapeutics的净亏损为126,408,000美元[34] - 截至2024年6月30日,CRISPR Therapeutics的现金及现金等价物为484,472,000美元,总资产为2,339,853,000美元,股东权益为1,980,949,000美元[35] 公司发展 - CRISPR Therapeutics已从一家研究阶段公司转变为一家最近获批首个CRISPR疗法的公司[28] - CRISPR Therapeutics与Bayer和Vertex Pharmaceuticals等领先公司建立了战略合作伙伴关系[28] - CRISPR Therapeutics的CRISPR/Cas9基因编辑技术已得到临床验证,具有创造潜在变革性药物的可能[28]

The market expects CRISPR Therapeutics AG (CRSP) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if the ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $57.19, indicating a +1.69% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.16% for the day. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, lost 0.06%.The company's shares have seen a decrease of 2.93% over the last month, not keeping up with the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96%.The investment community will be paying close attention to the ear ...

We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports second-quarter 2024 results next month.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteCRISPR Therapeutics’ top line comprises grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX) .Revenues in the last reported quarter solely comprised revenues from grants. The company did not record any collaboration revenues from Vertex in the first quarter. It remains to be s ...

They're small now, but these stocks could grow much larger.California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them.Three Motley Fool contributors think they've found biotech stocks that have the potential to become much larger. Here's why they think CRISPR Therapeutics (CRSP -2.94%), Zealand Pharma (ZLDP.F 0.89%), and Viking Therapeutics (VKTX 1.60%) are mon ...

Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals. This is mainly to explore potential cures for diseases that might affect humans.Other purposes of gene editing include making crops more resistant to viruses and bacteria and better able to cope with extremes of heat and cold caused by global warming. One day, gene editing could alter people’s DNA and prevent certain diseases from developin ...

Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies. These are becoming more precise and less time consuming, thus improving the effectiveness of the treatments and minimizing side effects. These are beneficial for the advancement of new generation therapies that can help cure genetic disorders. Lately, U.S. FDA approval of gene-editing treatments has validated this tech ...

CRISPR Therapeutics AG (CRSP) shares ended the last trading session 9.2% higher at $62.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% loss over the past four weeks.This rise in share price is attributable to positive investor expectations for the company’s sole-marketed product Casgevy which received marketing approval in late 2023/early 2024. Marketed in partnership with Vertex Pharmaceuticals, Casgevy is ...

These two stocks could have vastly different long-term performances.It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF, is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain.Of course, it's not hard to find stocks that have performed both better and worse than the sector average. Consider CRISPR Therapeutics (CRSP 0.96%), a mid-cap biotech that is down by 13% this year. On the other end of the spectrum is Ocugen (OCGN ...

The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $55.56, denoting a +0.96% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 1.02%. Elsewhere, the Dow gained 1.09%, while the tech-heavy Nasdaq added 1.18%.The company's stock has dropped by 11.68% in the past month, falling short of the Medical sector's loss of 1.82% and the S&P 500's gain of 4.44%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings d ...